- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Potentially Undervalued Companies
U.S. Pharmaceuticals & Biotech Potentially Undervalued Companies
UPDATED Mar 06, 2024
Companies with a Value score of at least 3, ordered by Value score
437 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| AZNAstraZeneca | UK£65.27 | -0.1% | 1.8% | UK£157.2b | UK£82.04 | PE33.6x | E16.7% | 2.2% | ||
| NVSNovartis | CHF102.64 | 0.4% | 23.2% | CHF186.1b | CHF108.77 | PE24.6x | E9.2% | 3.6% | ||
| VRTXVertex Pharmaceuticals | US$411.85 | -3.5% | 44.4% | US$107.3b | US$459.98 | PE29.4x | E11.2% | n/a | ||
| HMDC.FHUTCHMED (China) | UK£3.82 | 0% | 6.0% | UK£1.9b | UK£7.37 | PS3.2x | E31.1% | n/a | ||
| GABL.FGABY | CA$0.0014 | 0% | -61.8% | CA$3.7m | n/a | PE-0.08x | n/a | n/a | ||
| ALKS.VAlkermes | US$22.64 | n/a | n/a | US$3.9b | US$32.07 | PE18.2x | E12.3% | n/a | ||
| DMPH.FDermapharm Holding | €42.68 | 0% | n/a | €2.1b | €65.21 | PE11.7x | E1.2% | 5.7% | ||
| ARUX.FAcrux | AU$0.031 | 0% | n/a | AU$16.0m | n/a | PS1.4x | E115.3% | 0% | ||
| HNGZ.YHangzhou Tigermed Consulting | CN¥4.20 | 0% | n/a | CN¥36.2b | CN¥6.53 | PE16.8x | E12.7% | 1.2% | ||
| AKES.FAkeso | HK$5.70 | -2.7% | n/a | HK$37.8b | HK$7.11 | PE17.5x | E1.4% | n/a | ||
| EVOT.FEvotec | €13.83 | -4.0% | n/a | €2.3b | €24.91 | PS2.8x | E50.7% | n/a | ||
| RGNXREGENXBIO | US$24.00 | 20.6% | 4.5% | US$1.1b | US$38.55 | PS11.8x | E22.1% | n/a | ||
| AVTB.FAvant Brands | CA$0.074 | -19.2% | -47.6% | CA$29.3m | n/a | PS1.1x | n/a | n/a | ||
| ACETAdicet Bio | US$2.40 | 3.0% | -68.5% | US$190.4m | US$9.60 | PB1x | E6.0% | n/a | ||
| VORVor Biopharma | US$2.14 | -0.9% | -60.7% | US$148.5m | US$15.07 | PB0.8x | E4.8% | n/a | ||
| BIOQBioqual | US$75.25 | 7.5% | -8.2% | US$62.6m | n/a | PS1.1x | n/a | 0.7% | ||
| SHPH.FSihuan Pharmaceutical Holdings Group | HK$0.045 | n/a | n/a | HK$5.3b | n/a | PS2.8x | E119.4% | 0% | ||
| PAIO.FPaion | €0.025 | -64.1% | n/a | €230.4k | €7.65 | PE-0.01x | E69.1% | n/a | ||
| BNTCBenitec Biopharma | US$5.21 | 15.8% | 13.6% | US$13.8m | US$10.06 | PS221.4x | S-171.6% | n/a | ||
| ALLOAllogene Therapeutics | US$5.63 | 10.0% | -7.1% | US$908.7m | US$11.67 | PS5093.5x | E6.6% | n/a | ||
| IONSIonis Pharmaceuticals | US$44.29 | -4.8% | 24.3% | US$6.4b | US$56.72 | PS8.2x | E27.9% | n/a | ||
| GNMS.FGenmab | kr.293.58 | 6.7% | -15.6% | kr.129.6b | kr.362.95 | PE29.8x | E21.3% | n/a | ||
| BIO.BBio-Rad Laboratories | US$332.20 | 0.5% | n/a | US$9.4b | US$434.36 | PS3.6x | E81.3% | n/a | ||
| RLAYRelay Therapeutics | US$10.32 | 2.4% | -39.0% | US$1.3b | US$23.05 | PS53x | E-0.6% | n/a |